| Suspended | The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery NCT05727618 | Qianfoshan Hospital | N/A |
| Not Yet Recruiting | Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease NCT07473700 | Tectonic Operating Company, Inc. | Phase 2 |
| Recruiting | A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension NCT07079592 | National Defense Medical Center, Taiwan | N/A |
| Recruiting | Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead NCT07087613 | Eko Devices, Inc. | — |
| Recruiting | Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) NCT06814145 | Merck Sharp & Dohme LLC | Phase 2 |
| Withdrawn | Endovenous Sildenafil Early Management in Newborns Pulmonary Hypertension NCT04912726 | Universidad del Norte | N/A |
| Active Not Recruiting | Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD NCT05867914 | Third Pole Therapeutics, Inc. | N/A |
| Completed | Lung Hyperinflation and Response to Pulmonary Vasodilator Therapy NCT06613321 | Central Hospital, Nancy, France | — |
| Recruiting | Functional Pulmonary Capillary Surface Area in BPA for CTEPH NCT05719415 | Jewish General Hospital | N/A |
| Unknown | Telerehabilitation Program Via Videoconference PAH - Randomized Clinical Trial NCT05655481 | University of Nove de Julho | N/A |
| Completed | Piloting Mindfulness Meditation Program for Underserved Racial Minority Adults With Pulmonary Hypertension NCT05387889 | State University of New York at Buffalo | N/A |
| Recruiting | A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and H NCT05179876 | Actelion | Phase 3 |
| Completed | A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) NCT04945460 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 |
| Completed | A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertens NCT04732221 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Completed | A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study NCT04565990 | Actelion | Phase 3 |
| Completed | Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil NCT04697862 | University of Zurich | N/A |
| Completed | Hemodynamic Effects During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil NCT04706546 | University of Zurich | N/A |
| Unknown | Feasibility and Safety of Total Percutaneous Closure of Femoral Arterial Access Sites in the Veno-arterial ECM NCT04689451 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension With/Without Sildenafil NCT04704440 | University of Zurich | N/A |
| Completed | Hemodynamic Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension NCT04697875 | University of Zurich | N/A |
| Completed | Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hype NCT04715113 | University of Zurich | N/A |
| Completed | Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous A NCT04718350 | Aretaieion University Hospital | N/A |
| Terminated | A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH NCT04084678 | United Therapeutics | Phase 3 |
| Completed | A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Partici NCT04480723 | Actelion | EARLY_Phase 1 |
| Completed | Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension NCT04663217 | University of Giessen | — |
| Completed | Levosimendan Administration in Pulmonary Hypertension NCT04599816 | Aretaieion University Hospital | N/A |
| Unknown | THERAPY-HYBRID-BPA Trial NCT04600492 | National Hospital Organization Okayama Medical Center | Phase 2 |
| Unknown | Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness NCT04498299 | Miguel Ayala León | — |
| Completed | The Prevalence of Pulmonary Hypertension in Patients With COVID-19. NCT04459364 | Attgeno AB | — |
| Active Not Recruiting | A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension NCT04175600 | Actelion | Phase 3 |
| Completed | A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH) NCT04193046 | Janssen Research & Development, LLC | EARLY_Phase 1 |
| Completed | Effects of Inspiratory Muscle Training in Patients With Pulmonary Hypertension NCT04152187 | Dokuz Eylul University | N/A |
| Completed | Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants NCT04095286 | GlaxoSmithKline | Phase 1 |
| Enrolling By Invitation | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Exten NCT03683186 | United Therapeutics | Phase 3 |
| Completed | Acute Decompensation of Pulmonary Hypertension NCT03926572 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Pedometers and Walking Tests for Pulmonary Hypertension Patients NCT03810482 | University Hospital, Montpellier | N/A |
| Completed | This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With NCT03754660 | Bayer | Phase 1 |
| Completed | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients NCT03626688 | United Therapeutics | Phase 3 |
| Unknown | Inflammatory Biomarkers of Pediatric Pulmonary Hypertension NCT03581695 | The Hospital for Sick Children | — |
| Enrolling By Invitation | Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension NCT03388476 | University of Giessen | — |
| Terminated | ORal IrON Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension (ORION-PH-1) NCT03371173 | Hannover Medical School | Phase 3 |
| Completed | A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH) NCT03177603 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity NCT03293407 | Bayer | — |
| Completed | Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects NCT03304548 | GlaxoSmithKline | — |
| Terminated | Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension NCT03001414 | Northern Therapeutics | Phase 2 / Phase 3 |
| Completed | Aerobic Interval Training in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Hypoxemia NCT03092622 | Norwegian University of Science and Technology | N/A |
| Completed | Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension NCT02755259 | University of Zurich | Phase 2 / Phase 3 |
| Unknown | The Evaluation and Treatment of Elevated Left-Sided Filling Pressures by Balloon Inflation Within the IVC NCT02984631 | Cardioflow Technologies, LLC | N/A |
| Completed | Chronic Clinical Effect of Acetazolamide NCT02755298 | University of Zurich | Phase 2 / Phase 3 |
| Completed | Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. NCT02963597 | Albert Einstein Healthcare Network | N/A |
| Completed | Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary A NCT02826252 | Bayer | — |
| Completed | Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH) NCT02825160 | Bayer | — |
| Completed | A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. NCT02759419 | Bayer | Phase 4 |
| Terminated | Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial) NCT02435303 | Asan Medical Center | Phase 2 / Phase 3 |
| Completed | AZ, MZ, and the Pulmonary System Response to Hypoxia NCT02760121 | University of British Columbia | Phase 4 |
| Completed | A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy NCT02688387 | GlaxoSmithKline | Phase 1 |
| Completed | A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Cou NCT02637050 | Bayer | — |
| Withdrawn | Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion NCT02217683 | Massachusetts General Hospital | Phase 2 |
| Completed | Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fract NCT02744339 | Medical University of Vienna | Phase 2 |
| Completed | The Exercise Capacity and Quality of Life in the Patients With IPAH and Secondary PH NCT02647060 | National Taiwan University Hospital | — |
| Unknown | Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension. NCT03476629 | University of Nove de Julho | N/A |
| Completed | Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects a NCT02551653 | GlaxoSmithKline | Phase 1 |
| Completed | Estimation of Pulmonary Capillary Blood Volume in Pre- and Postcapillary Pulmonary Hypertension NCT02789449 | Medical University of Graz | — |
| Active Not Recruiting | Riociguat in Children With Pulmonary Arterial Hypertension (PAH) NCT02562235 | Bayer | Phase 3 |
| Completed | Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) NCT02576002 | Bayer | — |
| Terminated | Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension NCT03043976 | Imperial College Healthcare NHS Trust | N/A |
| Completed | A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Throm NCT02545465 | Bayer | — |
| Unknown | Effect of Exercise Training in Patients With Pulmonary Hypertension NCT02558582 | University of Zurich | N/A |
| Completed | Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension NCT02610660 | Association for Pediatric Pulmonary Hypertension | — |
| Completed | Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension NCT02536534 | Bayer | — |
| Completed | Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arte NCT02428985 | Bayer | — |
| Withdrawn | The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals NCT02560116 | Northwell Health | — |
| Completed | A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation NCT02305550 | Massachusetts General Hospital | N/A |
| Unknown | Catheter Denervation of Pulmonary Arteries in Treatment of IPAH & SPAH NCT02403908 | Clinical Hospital Centre Zagreb | Phase 1 |
| Unknown | Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionat NCT02298244 | Krasnoyarsk Regional Hospital | N/A |
| Completed | The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD NCT02267200 | Shanghai Jiao Tong University School of Medicine | — |
| Completed | Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) NCT02191137 | Bayer | Phase 4 |
| Completed | Measurement of Endothelial Function and Cardiac Output: New Methods NCT02299960 | Charite University, Berlin, Germany | — |
| Completed | Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thrombo NCT02117791 | Bayer | — |
| Completed | EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension NCT02092818 | Bayer | — |
| Completed | Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inh NCT02007629 | Bayer | Phase 3 |
| Completed | A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) NCT01824290 | Eli Lilly and Company | Phase 3 |
| Completed | Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Alti NCT02024386 | Richard Moon | Phase 4 |
| Completed | Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertensi NCT01971450 | Bayer | — |
| Completed | Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardi NCT01959828 | Mallinckrodt | Phase 3 |
| Completed | Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension NCT01642407 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 |
| Withdrawn | Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension NCT01523548 | University of Illinois at Chicago | Phase 1 / Phase 2 |
| Completed | Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study NCT01469169 | Bayer | Phase 3 |
| Completed | Dietary Nitrate for Heart Failure NCT01682356 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome NCT02661802 | Federal University of São Paulo | N/A |
| Completed | Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) NCT01462565 | GlaxoSmithKline | Phase 4 |
| Completed | Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD) NCT01361139 | Echosense Ltd. | — |
| Completed | Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life NCT01423071 | Wissenschaftliches Institut Bethanien e.V | — |
| Completed | Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia NCT01516398 | Stanford University | — |
| Completed | Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529 NCT01342952 | GlaxoSmithKline | Phase 2 |
| Terminated | Efficacy and Safety of Ambrisentan in Children 8-18yrs NCT01332331 | GlaxoSmithKline | Phase 2 |
| Completed | Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan NCT01281371 | Heidelberg University | — |
| Completed | Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension) NCT01406327 | GlaxoSmithKline | — |
| Terminated | Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients NCT01210443 | Pfizer | Phase 3 |
| Terminated | Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxat NCT01065051 | Bayer | Phase 2 |
| Completed | A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypert NCT01178073 | GlaxoSmithKline | Phase 3 |
| Completed | Endothelial Function in Patients With Pulmonary Arterial Hypertension NCT01317134 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Withdrawn | Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients NCT01202045 | Paul Farand | — |
| Terminated | A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients NCT01204853 | Pfizer | Phase 3 |
| Terminated | A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricu NCT01172756 | Bayer | Phase 2 |
| Completed | A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalaf NCT01305252 | Stanford University | Phase 4 |
| Completed | A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricu NCT01065454 | Bayer | Phase 2 |
| Completed | Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH) NCT01038284 | University Hospital, Grenoble | N/A |
| Completed | First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension NCT01247116 | University of Calgary | — |
| Completed | Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance NCT01212523 | University Hospitals Bristol and Weston NHS Foundation Trust | Phase 4 |
| Completed | Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed NCT01121458 | North Texas Veterans Healthcare System | Phase 4 |
| Completed | Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil NCT00963027 | United Therapeutics | Phase 1 |
| Completed | Effect of Food on the Pharmacokinetics of Oral Treprostinil NCT00963001 | United Therapeutics | Phase 1 |
| Terminated | A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatmen NCT00853112 | Pfizer | Phase 2 |
| Unknown | A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Asso NCT00864201 | Hamilton Health Sciences Corporation | Phase 3 |
| Completed | BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension NCT00863681 | Bayer | Phase 3 |
| Completed | Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension NCT00872170 | Carelon Research | Phase 2 / Phase 3 |
| Completed | Milrinone Inhaled in Cardiac Surgery NCT00819377 | Andre Denault | Phase 2 |
| Unknown | Simvatstatin Used to Treat Pulmonary Hypertension NCT00538044 | Capital Medical University | Phase 1 |
| Completed | Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension NCT00820352 | University Teaching Hospital Hall in Tirol | Phase 3 |
| Completed | Sildenafil IV Bolus Study NCT00800592 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 1 |
| Completed | Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID NCT00680654 | Bayer | Phase 1 |
| Terminated | Insulin Resistance in Pulmonary Arterial Hypertension NCT00825266 | Stanford University | Phase 2 |
| Completed | Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patie NCT00694850 | Bayer | Phase 2 |
| Completed | Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertens NCT00640315 | Bayer | Phase 1 |
| Completed | An Observational Study For Ambrisentan NCT00679224 | GlaxoSmithKline | — |
| Completed | Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults NCT01273259 | University Hospital, Bordeaux | Phase 2 |
| Terminated | Rapid Switch From Flolan to Remodulin in the Outpatient Clinic NCT00643604 | United Therapeutics | Phase 4 |
| Completed | A Study to Evaluate GSK1325760A - a Long-Term Extension Study NCT00554619 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hyper NCT00540436 | GlaxoSmithKline | Phase 2 |
| Completed | Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis NCT00517933 | Duke University | Phase 3 |
| Terminated | Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to L NCT00458276 | Idorsia Pharmaceuticals Ltd. | Phase 3 |
| Terminated | Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction NCT00458042 | United Therapeutics | Phase 4 |
| Completed | Atorvastatin in Pulmonary Hypertension NCT00615823 | Chinese Academy of Medical Sciences, Fuwai Hospital | Phase 2 |
| Unknown | Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults NCT00581087 | University Hospital, Bordeaux | Phase 3 |
| Completed | An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension NCT00454558 | Bayer | Phase 2 |
| Terminated | A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension NCT00384865 | University of Pennsylvania | Phase 2 |
| Completed | Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis NCT00359736 | VA Office of Research and Development | Phase 2 |
| Completed | Pulmonary Artery Remodelling With Bosentan NCT00595049 | Actelion | Phase 4 |
| Completed | Pulmonary Hypertension: Assessment of Cell Therapy NCT00469027 | Northern Therapeutics | Phase 1 |
| Completed | Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery NCT00335244 | Asklepion Pharmaceuticals, LLC | Phase 3 |
| Terminated | Chronic Sildenafil for Severe Diaphragmatic Hernia NCT00133679 | University of California, San Francisco | Phase 4 |
| Completed | Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Hear NCT00549302 | Eli Lilly and Company | Phase 3 |
| Completed | Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension NCT00240656 | Hebei Medical University | Phase 1 |
| Completed | Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy R NCT00250640 | Bayer | — |
| Completed | Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hyper NCT00352482 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Genetic and Environmental Characteristics of Primary Pulmonary Hypertension NCT00091546 | Vanderbilt University | — |
| Completed | The Effect of Tracleer® on Male Fertility NCT00082186 | Actelion | Phase 4 |
| Completed | A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment NCT00644605 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 |
| Completed | A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension NCT00105209 | Kawut, Steven, MD | Phase 2 |
| Terminated | Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure NCT00016523 | NICHD Neonatal Research Network | Phase 3 |
| Completed | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) NCT00000623 | Carelon Research | — |
| Completed | Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension NCT00185315 | Bayer | Phase 3 |
| Terminated | Safety of Terbogrel in Patients With Primary Pulmonary Hypertension NCT02223494 | Boehringer Ingelheim | Phase 2 |
| Terminated | Early Inhaled Nitric Oxide for Respiratory Failure in Newborns NCT00005773 | NICHD Neonatal Research Network | Phase 3 |
| Completed | Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Il NCT00414687 | Bayer | Phase 2 |
| Completed | Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension NCT02223481 | Boehringer Ingelheim | Phase 2 |
| Terminated | Inhaled Nitric Oxide Study for Respiratory Failure in Newborns NCT00005776 | NICHD Neonatal Research Network | Phase 3 |
| Completed | Pulmonary Hypertension--Mechanisms and Family Registry NCT00005357 | Vanderbilt University | — |
| Completed | Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension NCT00004754 | National Center for Research Resources (NCRR) | Phase 4 |
| Withdrawn | Study of the Effects of Iron on Lung Blood Pressure at High Altitude NCT00960921 | University of Oxford | Phase 2 |
| No Longer Available | Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) NCT01784562 | Bayer | — |
| Withdrawn | Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension NCT00780728 | University Health Network, Toronto | Phase 3 |